Lilial is a privately owned, French direct-to consumer home delivery company with nationwide distribution of primarily catheter and ostomy supplies founded in 2003. Lilial provides patients with products from several different manufacturers including Coloplast. The company has approx. 80 employees and is expected to record sales of approx. EUR 33m or approx. DKK 246m for the full-year 2017.

The acquisition is a continuation of Coloplast’s overall ambition to secure its end users innovative products and services. Furthermore, the acquisition strengthens Coloplast’s position and offering in France, where Coloplast expects to continue to work closely with healthcare professionals and channel partners with the intent of improving overall end user outcomes.

“The acquisition of SAS Lilial is part of our strategy of pursuing inorganic opportunities to accelerate growth and to strengthen our service offerings. By acquiring Lilial we further strengthen our position in France and ensure our end users access to innovative products and services. Lilial is a great match for Coloplast, and I am very happy to welcome Lilial to the Coloplast family,” said Coloplast CEO Lars Rasmussen.

The acquisition leads to a revised financial guidance for the financial year 2017/18:

The organic revenue growth guidance of ~7% is unchanged. The growth in DKK of 5-6% based on spot rates as of 31 October 2017, is expected to be ~1%-points higher.

The EBIT margin guidance of 31-32% in constant exchange rates and about 31% in DKK is unchanged.

The transaction is expected to contribute to Coloplast’s long-term growth ambition. The long-term guidance for the LEAD 20 strategy period until fiscal year-end 2019/20 of 7-9% organic growth p.a. and an EBIT margin of more than 30% in constant currencies is unchanged.

For more information on Lilial please refer to www.lilial.fr

dkebj@coloplast.com  

Coloplast is presenting a new long-term guidance for the LEAD20 strategy period. This new guidance is driven by changing market dynamics which create opportunities to accelerate growth. Furthermore, Coloplast intends to pursue inorganic opportunities to further strengthen our service offering to the consumer. Organic revenue growth guidance is maintained at 7-9% p.a., and the ambition is to reach the upper end of the interval. Consequently, the EBIT margin guidance is changed from a 50-100 basis point improvement p.a., to a guidance of delivering an EBIT margin of more than 30% in constant currencies.

Coloplast delivered organic growth of 8% in the fourth quarter of the 2016/17 financial year, equal to a 6% revenue increase to DKK 3,980m when measured in Danish kroner.

For the full-year, Coloplast delivered 7% organic revenue growth. When measured in Danish kroner, full-year revenue was up by 6% to DKK 15,528m.

EBIT amounted to DKK 5,024m adjusted for the one-off payment to Veterans Affairs, a 9% increase at constant exchange rates (4% in DKK). The EBIT margin was 33% at constant exchange rates and adjusted for the one-off payment to Veterans Affairs, which was in line with last year’s EBIT margin. The result is consistent with the company’s guidance.

Full-year organic growth rates by business area: Ostomy Care 7%, Continence Care 7%, Urology Care 10%, and Wound & Skin Care 4%. Several major product launches contributed to the organic growth, including SenSura® Mio Convex, SpeediCath® Flex and Brava® Protective Seal.

Full-year organic growth rates by sales region: European markets 5%, Other Developed Markets 8% and Emerging Markets 13%.

“We’re delivering a strong fourth quarter and satisfactory full-year results driven by solid growth in Europe and accelerated momentum in Emerging Markets and Other Developed Markets. The 2016/17 financial year was characterised by several product launches, all of which contributed to the organic growth. Our full-year growth rate was well above the global market growth, and we continued to gain market share across all business areas,” said Coloplast CEO Lars Rasmussen.

“Furthermore, we are presenting a new long-term financial guidance for our global strategy towards 2020. This is driven by changing market dynamics and opportunities to further accelerate growth,” said Mr Rasmussen.

New plan for Global Operations

A new Global Operations Plan is being introduced as part of Coloplast’s global strategy towards 2020. The plan is to deliver EBIT margin improvements of about 150 basis points with full effect from the 2020/2021 financial year.

As part of the Global Operations Plan, Coloplast expects to consolidate all pilot activities at Coloplast’s innovation site in Mørdrup, north of Copenhagen, and phase out the Thisted factory over a two-year period.

Financial guidance 2017/18
Coloplast is expecting organic revenue growth of about 7% at constant exchange rates and of 5-6% in Danish kroner. The guidance includes a potential negative effect of DKK 100m due to the patent expiry of SpeediCath® standard catheters. The guidance also includes the effects of a comprehensive healthcare reform in Greece of DKK 100m, which is expected to impact all business areas, resulting in a price pressure of more than 1% in the year.

The EBIT margin is expected to be 31-32% at constant exchange rates and about 31% in Danish kroner. The EBIT margin guidance is impacted by an increase in commercial investments from about 1% of the revenue to about 2% of the revenue.

Capital expenditure is expected to be about DKK 700m, and the effective tax rate is expected to be about 23%.

Coloplast’s Annual Report and Corporate Responsibility Report will be released later today.

Click here https://www.coloplast.com/investor-relations/annual-reports/ to read the Annual Report and here https://www.coloplast.com/about-coloplast/responsibility/policies/ to read Coloplast’s Corporate Responsibility Report.

dkebj@coloplast.com

Coloplast delivered organic growth of 8% in the third quarter of the 2016/17 financial year. When measured in Danish kroner, revenue was up by 6% to DKK 3,912m.

Reported Q3 revenue was adversely affected by a DKK 90m one-off revenue adjustment made after Coloplast identified incorrect management of contractual obligations relating to an agreement with the U.S. Department of Veterans Affairs for the period 2009-2017. The matter relates to continence care products and has not affected the organic growth rate for the reporting period. Coloplast has recently renewed the contract with the U.S. Department of Veterans Affairs and the company has now opened a dialogue with the U.S. Department of Veterans Affairs in order to resolve the matter.

EBIT was up by 9% at constant exchange rates, adjusted for the one-off revenue adjustment for the U.S. Department of Veterans Affairs for, and up by 4% in DKK to DKK 3,705m. The EBIT margin was at 33% at constant exchange rates and before the one-off adjustment, which was in line with last year’s percentage.

Q3 organic growth rates by business area: Ostomy Care 7%, Continence Care 10%, Urology Care 10%, and Wound & Skin Care 1%.

By geographies, the European markets contributed 4% growth. “Other established markets” and Emerging Markets both delivered 14% revenue growth.

-        “We’re delivering a satisfactory Q3 result with many of our major markets performing well, including the UK and the USA. The integration of Comfort Medical in the USA continues to progress to plan, and our US Chronic Care business reported double-digit organic sales growth in the third quarter. Also, our Emerging Markets business delivered 14% organic growth in the third quarter, driven by strong growth momentum in China and Russia,” said Coloplast CEO Lars Rasmussen. 

-        “Pricing reforms in Greece and France had a negative impact on sales growth in the Wound and Skin Care business in the third quarter, but the effect was offset by a stronger momentum for the Wound Care business in China and for the Skin Care business in the USA,” said Mr Rasmussen.

New products to drive growth

Coloplast continues to launch new products in all core markets, including the SpeediCath® Flex catheter, which is now available in fourteen markets. Feedback on the product has been very positive.

In the Ostomy Care business, Coloplast is now relaunching the SenSura® Mio Convex, after having expanded production capacity in Hungary to accommodate market demand. The relaunch is progressing to plan.

Financial guidance for 2016/17

We continue to expect organic revenue growth of 7–8% at constant exchange rates. The guidance for organic revenue growth has not been affected by the one-off revenue adjustment of DKK 90m. The guidance for reported revenue growth is revised to 6% in DKK instead of as previously 7–8%, due to the one-off revenue adjustment of DKK 90m and to exchange rate developments with especially the depreciation of the USD and GBP having a negative impact. 

The EBIT margin guidance remains at 33–34% at constant exchange rates. The EBIT margin guidance at constant exchange rates includes the one-off revenue adjustment of DKK 90m. The reported EBIT margin guidance in DKK is revised to about 32% instead of as previously about 33%, due to the one-off revenue adjustment of DKK 90m and to exchange rate developments with especially the depreciation of the USD and GBP having a negative impact. 

In the second quarter of the 2016/17 financial year, Coloplast delivered 8% growth measured in Danish kroner corresponding to DKK 3,881m, and 7% organic revenue growth. EBIT was up by 7% to DKK 1,246m and net profit for the Q2 reporting period was up by 2% to DKK 931m.

Organic growth rates by business area were: Ostomy Care 7%, Continence Care 8%, Urology Care 14%, and Wound & Skin Care negative 4%.

Geographically, the European markets contributed 5% growth with the UK and France as the standouts. Other established markets delivered 8% growth, while Emerging markets delivered 10% growth.

“We’re delivering a satisfactory Q2 result with many of our European markets performing well. In addition, the integration of Comfort Medical in the US is progressing according to plan and our US Chronic Care business reported double-digit sales growth in the second quarter after inventory levels at our large distributors had been normalised in the first quarter. That is having a positive effect on our Ostomy Care and Continence Care businesses, and we expect continued positive sales growth in our US business in the coming quarters. Currency developments continued to have a negative effect on reported sales as well as earnings, while the acquisition of Comfort Medical had a positive effect on reported sales in the quarter,” said Coloplast CEO Lars Rasmussen.

“Sales growth in the Wound and Skin Care business was adversely affected by a very strong performance of the US Skin Care business in the second quarter of last year. On the other hand, the Wound Care business in China reported positive momentum in the second quarter, which we expect will continue in the coming quarters,” said Mr Rasmussen. 

New products to drive growth

Coloplast continues to launch new products in all core markets, including the SpeediCath® Flex catheter and the Biatain® Silicone Sizes & Shapes wound care portfolio. Both products have received very positive feedback.

In the Ostomy Care business, Coloplast is now relaunching the SenSura® Mio Convex, having expanded production capacity in Hungary to accommodate market demand. In addition, the new SenSura® Mio Hospital portfolio will be available in all core markets over the next 12 months, and the Brava® Protective Seal accessory product is now available in 13 countries.

Financial guidance for 2016/17

Coloplast maintains its guidance for organic revenue growth of 7-8% at constant exchange rates and reported growth of 7-8% in DKK. The EBIT margin guidance remains at 33-34% at constant exchange rates and at about 33% in DKK.

CONTACTS

Dennis Kaysen

Director, Corporate Communications

+45 49 11 26 08

dkdk@coloplast.com

Ellen Bjurgert

Director, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com

Since 1954, the Red Dot Award has been a global benchmark for design and innovation focusing on the user experience and aesthetics of a wide range of consumer products. This year, Red Dot received 5500 submissions from 54 countries and all of the products entered were assessed by an independent and international jury of experts.

Professor Dr. Peter Zec, founder and CEO of the Red Dot Award: “The Red Dot winners are pursuing the right design strategy. They have recognised that good design and economic success go hand in hand. The award by the critical Red Dot jury documents their high design quality and is indicative of their successful design policy.”

Coloplast Wound Care’s entry of the Biatain Silicone sizes & shapes, has been measured successfully against innovative design across various industries and awarded a Red Dot Award as one of the globally most outstanding product designs in 2017. 

The Biatain Silicone products are soft, flexible, absorbent foam dressings with a silicone adhesive used for treating chronic and acute wounds. Biatain Silicone sizes & shapes was launched in 2016 as an extension to the Biatain Silicone product range with eight new sizes and shapes designed to conform to the different areas of the body. 

The new products have been launched across 14 markets globally.

Accelerating Wound Care growth

“We are very proud and pleased to have won a Red Dot Award, which is an internationally recognised quality label for great design. The Biatain Silicone sizes & shapes products are designed according to the Coloplast Design DNA, meaning that our users will experience not only a product which provides superior absorption and faster healing, but also an intuitive and non-medical looking product with a life-style oriented design” says Nicolai Buhl, Senior Vice President in Coloplast Wound & Skin Care.

“The launch of the Biatain Silicone range has accelerated the Coloplast Wound Care growth in recent years, and with the extension of the range, we believe we can accelerate growth even further”, Nicolai ends.

In July 2017, the design team behind Biatain Silicone Sizes & Shapes are going to Essen, Germany to receive the award at the Red Dot Gala.

CONTACTS

Coloplast delivered organic growth of 6% in the first three months of the 2016/17financial year, increasing revenue measured in Danish kroner by 3% to DKK 3,755m.EBIT increased by 3% to reach DKK 1,226m, while the profit for the period was up by 15% to DKK 946m.

Coloplast continued to generate growth in all business areas in the first quarter,delivering organic growth in Ostomy Care at 6%, Continence Care at 5%, Wound & Skin Care at 5% and Urology Care at 8%.

In Continence Care, Coloplast recently launched a new flexible catheter for men, the SpeediCath Flex. The product is now on the market in 11 countries. In addition, in Wound & Skin Care, the Biatain Silicone Sizes & Shapes product portfolio had been launched in eight countries on 1 January. Both launches have received very positive feedback from users and healthcare professionals.

Geographically, Europe was the main growth driver overall, delivering 6% organic growth, with sales growth in the UK and France standing out. Other developed markets produced 4% growth, while Emerging Markets contributed 7%.

“We delivered satisfactory results in the first quarter of the year, supported by a particularly strong performance of our European business. Growth in the US was affected by inventory reductions of large distributors. Inventory levels are now back to normal, and we expect this to drive favourable sales growth developments in the coming quarters,” says Lars Rasmussen, CEO of Coloplast.

In a move to support the overall ambition of bringing innovative products and services to the US market, Coloplast acquired US distributor Comfort Medical in November. The acquisition was approved in late December, and the process of integrating the company has now been set in motion.

Coloplast continues to expect an organic revenue growth of 7-8% at constant exchange rates. Coloplast now expects organic revenue growth of 7-8% in Danish kroner (DKK) following the acquisition of Comfort Medical and developments in the British pound and the US dollar. Coloplast continues to expect the EBIT margin to be33-34% at constant exchange rates and about 33% in DKK.

CONTACTS

Maria Lindeberg

Senior Media Relations Manager

+45 49 11 30 95

dkmalg@coloplast.com

Ellen Bjurgert

Director, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com